Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 21;5(1):vdad075.
doi: 10.1093/noajnl/vdad075. eCollection 2023 Jan-Dec.

Glioblastoma lacking necrosis or vascular proliferations: Different clinical presentation but similar outcome, regardless of histology or isolated TERT promoter mutation

Maarten M J Wijnenga  1 , Sybren L N Maas  2   3 , Vera van Dis  2 , C Mircea S Tesileanu  1 , Johan M Kros  2 , Linda Dirven  4 , Hans M Hazelbag  5 , Hendrikus J Dubbink  2 , Arnaud J P E Vincent  6 , Pim J French  1 , Martin J van den Bent  1
Affiliations

Glioblastoma lacking necrosis or vascular proliferations: Different clinical presentation but similar outcome, regardless of histology or isolated TERT promoter mutation

Maarten M J Wijnenga et al. Neurooncol Adv. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Panel A: overall survival curves for histological grades in m-GBM and the h-GBM cohort. Survival was defined as time from first surgery till date of death or censorship. OS for grade 2 patients was 17 months versus 18 months in h-GBM patients. Panel B: overall survival curves of grade 2 patients within the m-GBM group; patients with an isolated TERTp mutation (so absence of EGFR amplification and/or 7+/10−) versus patients with an EGFR amplification and/or 7+/10− with or without a TERTp mutation (all but 2 of these patients also harbored a TERTp mutation). OS was 17 months for isolated TERTp mutation versus 21 months for patients with EGFR amplification and/or 7+/10−.
See this image and copyright information in PMC

References

    1. Louis DN, Perry A, Wesseling P, et al. . The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 2021;23(8):1231–1251. - PMC - PubMed
    1. Lassman AB, van den Bent MJ.. What is a glioblastoma? Neuro Oncol. 2023;25(6):1015–1016. - PMC - PubMed
    1. Berzero G, Di Stefano AL, Ronchi S, et al. . IDH-wildtype lower-grade diffuse gliomas: The importance of histological grade and molecular assessment for prognostic stratification. Neuro Oncol. 2021;23(6):955–966. - PMC - PubMed
    1. Tesileanu CMS, Dirven L, Wijnenga MMJ, et al. . Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: A confirmation of the cIMPACT-NOW criteria. Neuro Oncol. 2020;22(4):515–523. - PMC - PubMed
    1. van Opijnen MP, Tesileanu CMS, Dirven L, et al. . IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas. Neuro Oncol. 2023;25(4):701–709. - PMC - PubMed

LinkOut - more resources